Shares of Ventrus Biosciences Inc (VTUS) saw unusually high trading volume on Monday. Approximately 91,941 shares changed hands during mid-day trading, an increase of 20.13% from the previous session. The stock last traded at $14.82.
Separately, analysts at Rodman & Renshaw initiated coverage on shares of Ventrus Biosciences Inc in a research note to investors on Wednesday, February 2nd. They set an “outperform” rating and a $12.00 price target on the stock. Also, analysts at National Securities initiated coverage on shares of Ventrus Biosciences Inc in a research note to investors on Friday, January 28th. They set a “buy” rating on the stock.
Ventrus Biosciences, Inc. (Ventrus) is a specialty pharmaceutical company focused on the development and commercialization of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence. Its product candidate portfolio consists of three late-stage drugs intended to treat these conditions: one new chemical entity (NCE) and two previously approved molecules that will have market exclusivity for new and patentable topical gastrointestinal indications. The Company’s three late-stage product candidates are Iferanserin ointment (VEN 309) for the treatment of hemorrhoids, Diltiazem cream (VEN 307), a treatment for the relief of pain associated with anal fissures and Phenylephrine gel (VEN 308) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis (IPAA).
Ventrus Biosciences Inc has a 52 week low of $5.75 and a 52 week high of $15.00. The stock’s 50-day moving average is $10.87 and its 200-day moving average is $8.42. The company has a market cap of $100.0 million.
Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.
没有评论:
发表评论